Steroids

Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, August 4, 2021

ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2million in Q2 2021, reflecting growth of 15% over the previous quarter

Key Points: 
  • ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2million in Q2 2021, reflecting growth of 15% over the previous quarter
    Net loss in Q2 2021 decreased by $10.4million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA sales
    BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June30, 2021.
  • Net sales of ZILRETTA were $28.2million and $15.5million for the three months ended June30, 2021 and 2020, respectively.
  • Loss per share for the second quarter of 2021 was $0.44, compared to $0.76 for the same period of 2020.
  • Research and development expenses were $12.7million and $12.5million for the three months ended June30, 2021 and 2020, respectively.

EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)

Retrieved on: 
Monday, July 19, 2021

"Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment ofplaque psoriasis, with proven efficacy, safety and tolerability.

Key Points: 
  • "Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment ofplaque psoriasis, with proven efficacy, safety and tolerability.
  • Until now they could not be combinedinto an aqueous cream, which is less greasy and more user-friendly than other formulations."
  • Wynzora Cream is based on PADTechnology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in aconvenient-to-use aqueous formulation.
  • Wynzora (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis inadults.It is notknown ifWynzoraCream is safeand effectivein children.

EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)

Retrieved on: 
Monday, July 19, 2021

Now available: Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age orolderintroduces useof PAD Technology.

Key Points: 
  • Now available: Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age orolderintroduces useof PAD Technology.
  • "Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment ofplaque psoriasis, with proven efficacy, safety and tolerability.
  • Wynzora Cream is based on PADTechnology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in aconvenient-to-use aqueous formulation.
  • Wynzora (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis inadults.It is notknown ifWynzoraCream is safeand effectivein children.

Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Conference

Retrieved on: 
Wednesday, July 7, 2021

EWING, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference.

Key Points: 
  • EWING, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference.
  • Details of the presentation are as follows:
    A live webcast of the presentation will be available under the For Investors section of the Antares Pharma website at www.antarespharma.com.
  • Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas such as urology and endocrinology.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

Lipocine To Present At The Ladenburg Thalmann Healthcare Conference

Retrieved on: 
Tuesday, July 6, 2021

SALT LAKE CITY, July 6, 2021 /PRNewswire/ --Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference.

Key Points: 
  • SALT LAKE CITY, July 6, 2021 /PRNewswire/ --Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference.
  • The webcast of this presentation will also be available on Lipocine's corporate website under "Events & Presentations" in the Investors section.
  • Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies.
  • TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing.

Lipocine To Present At The Raymond James Human Health Innovation Conference

Retrieved on: 
Wednesday, June 16, 2021

SALT LAKE CITY, June 16, 2021 /PRNewswire/ --Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James Human Health Innovation Conference.The conference will be held virtually.

Key Points: 
  • SALT LAKE CITY, June 16, 2021 /PRNewswire/ --Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James Human Health Innovation Conference.The conference will be held virtually.
  • The webcast of this presentation will also be available on Lipocine's corporate website under "Events & Presentations" in the Investors section.
  • Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies.
  • TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing.

Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO® Hydrocortisone Autoinjector

Retrieved on: 
Tuesday, June 15, 2021

The ZENEO autoinjector is a revolutionary delivery system, and this product is a terrific strategic fit with our current adrenal insufficiency business.

Key Points: 
  • The ZENEO autoinjector is a revolutionary delivery system, and this product is a terrific strategic fit with our current adrenal insufficiency business.
  • ETON has successfully established strong relations with the patient communities and medical specialists that are its core focus.
  • ZENEO hydrocortisone is expected to be the first and only hydrocortisone autoinjector available for patients that require a rescue dose of hydrocortisone.
  • Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

Antares Pharma to Present at the Raymond James Human Health Innovations Conference

Retrieved on: 
Tuesday, June 15, 2021

EWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Raymond James Human Health Innovations Conference.

Key Points: 
  • EWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Raymond James Human Health Innovations Conference.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

Marius Announces Ambulatory Blood Pressure Results Published in the Journal of Clinical Hypertension with their new testosterone medication KYZATREX™

Retrieved on: 
Friday, June 11, 2021

Effects of Oral Testosterone Undecanoate KYZATREX on Ambulatory Blood Pressure in Hypogonadal Men was published by William B.

Key Points: 
  • Effects of Oral Testosterone Undecanoate KYZATREX on Ambulatory Blood Pressure in Hypogonadal Men was published by William B.
  • The publication of these results marks a significant milestone in the field of testosterone therapy as ambulatory blood pressure monitoring (ABPM) is the most accurate means to detect small BP changes in clinical trials and practice.
  • commented, The changes in ambulatory BP were quite minimal in our study and of no clinical significance in normotensive men, a first in the testosterone space.
  • Shalin Shah, Co-CEO of Marius commented, We are extremely proud of the blood pressure data produced across all patient groups.

Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference

Retrieved on: 
Monday, June 7, 2021

SALT LAKE CITY, June 7, 2021 /PRNewswire/ --Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Lytham Partners Summer 2021 Investor Conference.The conference will be held virtually.

Key Points: 
  • SALT LAKE CITY, June 7, 2021 /PRNewswire/ --Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Lytham Partners Summer 2021 Investor Conference.The conference will be held virtually.
  • The webcast of this presentation will also be available on Lipocine's corporate website under "Events & Presentations" in the Investors section.
  • Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies.
  • TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing.